At Talis, we strive for excellence in all we do.

Talis

Adjective –
talis (neuter tale); third declension; latin
distinguished; great; excellent

Why we’re here

Because infectious disease diagnosis is a race against time.

What we’re striving for

Rapid and accurate diagnosis of infectious diseases at the point of need.

The change we’re bringing

When it comes to infectious diseases, a quick and accurate diagnosis can make a big difference for both the patient and for the community.

An appropriate treatment plan can be selected and started to stop disease progression and, as the COVID-19 pandemic demonstrated, rapid diagnosis can identify individuals who may need to quarantine to prevent widespread transmission of the disease.

Current infectious disease diagnosis technology is not geared for rapid delivery of results. Many molecular diagnostic tests are complex and time-consuming to execute and must be performed in a central lab. This can delay diagnosis for days.

Talis believed there had to be a better way.

By carefully analyzing the molecular diagnostic testing workflow and understanding which steps were critical for enabling the maximum amount of accuracy for infections disease identification, the team at Talis is developing a highly robust infectious disease testing solution–The Talis One.

Delivering the accuracy and quality of a central lab molecular diagnostic test at the time and place where it’s needed most–the doctor’s office–our company is ready to change the way we diagnose infectious disease with Talis One.

The Talis Team

Kim Popovits

Interim Chief Executive Officer

Kim Popovits is the interim CEO of Talis. Prior to this appointment in August 2021, she served on the company’s board of directors since March 2020. Ms. Popovits is the former Chairman of the Board, President and Chief Executive Officer of Genomic Health. Under her leadership Genomic Health became the world’s leading provider of genomic-based diagnostic tests that optimized the treatment of cancer, resulting in an acquisition by Exact Sciences in November 2019. Prior to Genomic Health, Ms. Popovits held several senior management roles at Genentech where she led the commercialization of 14 new therapeutics. Ms. Popovits serves on the boards of 10x Genomics, Kiniksa Pharmaceuticals, Ltd., the Coalition for 21st Century Medicine and the Personalized Medicine Coalition. She also serves as an Executive Advisor to Blackstone Life Sciences and is an Advisor to the Healthcare Businesswomen’s Association (HBA). Ms. Popovits received a B.A. in Business from Michigan State University.

Roger Moody

Chief Financial Officer

Roger Moody has served as our Chief Financial Officer since May 2020. From August 2017 to May 2020, Mr. Moody was Chief Financial Officer of Clinical Genomics, Inc., a colorectal cancer diagnostics company. From July 2015 to August 2017, Mr. Moody was Chief Executive Officer and a member of the board of directors of GlySure Limited, a medical device company, and from February 2015 to July 2015 he was Chief Operating Officer of GlySure. Prior to GlySure, Mr. Moody served as the Chief Financial Officer and Vice President of Finance & Administration of Nanosphere, Inc., a publicly held molecular diagnostics platform company, from May 2007 to February 2015. Mr. Moody received a B.S. in Finance from Syracuse University and an M.B.A. from the University of Chicago.

Douglas Liu

Chief Operating Officer

Douglas Liu has served as our Chief Operating Officer since July 2021. Prior to this role, he was Talis’s Senior Vice President, Operations. From July 2005 to September 2020, Mr. Liu was Senior Vice President, Global Operations at QIAGEN N.V., a publicly held biotechnology company. From July 1996 to July 2005, Mr. Liu was Director of Operations at Bayer AG, a publicly held pharmaceutical company. Prior to Bayer AG, Mr. Liu served as Project Manager, Research and Development at Abbott Laboratories, a publicly held medical device and healthcare company, from May 1986 to July 1996. Mr. Liu received a B.S. in Agriculture from the University of Illinois at Urbana-Champaign and an M.B.A. from Boston University.

Rob Kelley

Chief Commercial Officer

Rob Kelley has served as our Chief Commercial Officer since September 2020. From October 2017 to August 2020, Mr. Kelley was Vice President, Sales and Commercial Development of Genalyte, Inc., a healthcare analytics and point-of-care diagnostics company. Prior to Genalyte, Mr. Kelley was Vice President, Marketing of Cardiff Oncology, Inc., a publicly held liquid biopsy company (formerly Trovagene, Inc.), from March 2015 to May 2017. From December 2008 to March 2015, Mr. Kelley held various positions of increasing responsibility with Illumina Inc., a publicly held biotechnology company, including Global Sales Manager for clinical applications of NGS and Director, Market Development, New and Emerging Opportunities. Mr. Kelley received a B.S. in Biology from Duke University and an M.B.A. from the UCLA Anderson School of Management.

Karen E. Flick, J.D., Ph.D.

Chief of Staff and Senior Vice President, Legal

Karen E. Flick, J.D., Ph.D. has served as our Chief of Staff and Senior Vice President, Legal since February 2020. Previously, Dr. Flick served as our Vice President, Legal from April 2019 to February 2020 and as our Intellectual Property Counsel from January 2015 to April 2019. Prior to Talis, Dr. Flick practiced law as a patent agent from 1998 to 2002 and as a patent attorney from 2002 to December 2014 at several prominent law firms, including Foley & Lardner LLP, Fish & Richardson P.C. and Cooley LLP. Dr. Flick holds an A.B. in Biomedical Sciences from Harvard College, and earned her J.D. and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Emily Faucette

Senior Vice President, Communications & IR

Ms. Faucette has more than 25 years of healthcare communications experience across corporate, product and investor relations. Prior to joining Talis, Ms. Faucette served as Senior Vice President of Global Corporate Affairs & Investor Relations at Portola Pharmaceuticals, where she was responsible for integrated global communications, including public relations, patient advocacy and investor relations. She also led the communications strategy to represent Portola’s point of view in the announcement of and integration for an acquisition by Alexion Pharmaceuticals that closed in July 2020. Prior to Portola, Ms. Faucette spent 13 years at Genomic Health up to its acquisition by Exact Sciences for $3B in 2019. While at Genomic Health, she helped establish and expand a best-in-class global communications team that led public relations, investor relations, patient advocacy, corporate, product and employee communications, digital marketing, and branding. Ms. Faucette began her career in the healthcare communications agency setting with ten years of experience between WeissComm Partners (now Real Chemistry) and Ketchum. Ms. Faucette earned a B.A. in public communications from American University.

Marilee Moy

Vice President, Human Resources

Marilee Moy brings over 30 years of Human Resources domestic and international leadership experience in world class life sciences and technology companies ranging from start-ups to international, public companies. Prior to joining Talis, she served in leadership roles at Johnson & Johnson, Abbott Laboratories, Genentech, Nikon Precision, Questcor Pharmaceuticals (acquired by Mallinckrodt) and Counsyl (acquired by Myriad Genetics). Her passions include leading as a strategic business partner, attracting and nurturing talent and diversity to grow a thriving organization. She’s enabled Talis to grow headcount over 450% since she joined in 2018 and is focused on promoting a strong and vital culture. She holds a B.A. from Boston College, an M.B.A. from Golden Gate University, and a strategic human resources executive certification from the University of Michigan, Ann Arbor.

Board of Directors

Felix Baker, Ph.D.

Felix Baker, Ph.D. has served as a member of our board of directors since June 2013. Dr. Baker is a Managing Member and Co-Founder of Baker Bros. Advisors LP, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Dr. Baker has served on the board of directors of Seagen, Inc. (previously Seattle Genetics, Inc.) since July 2003, Kodiak Sciences, Inc. since September 2015, Kiniksa Pharmaceuticals, Ltd. since October 2015 and IGM Biosciences, Inc. since January 2021. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

View Linkedin Profile

Raymond Cheong, M.D., Ph.D.

Raymond Cheong, M.D., Ph.D. has served on our board of directors since June 2020. Dr. Cheong is a Principal at Baker Bros., where he has worked since 2013. Dr. Cheong has also served on the board of directors of Istari Oncology, Inc., a biotechnology company focused on immuno-oncology and immunotherapy platforms, since December 2018. Dr. Cheong received a B.S. in Chemical Engineering from the University of Maryland, College Park, and an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University, where he was awarded the Michael A. Shanoff Award for best thesis research.

View Linkedin Profile

Melissa Gilliam, M.D., M.P.H.

Melissa Gilliam, M.D., M.P.H. has served on our board of directors since December 2020.  She is a highly accomplished physician and research scientist with an academic background rooted in the humanities and a lifelong dedication to service. Dr. Gilliam is the executive vice president and provost at The Ohio State University. In this role, she is the chief academic officer of one of the largest and most comprehensive universities in the country. Prior to joining The Ohio State University, Melissa Gilliam was the Ellen H. Block Distinguished Service Professor of Health Justice and Vice Provost. She has taught as a Professor of Obstetrics and Gynecology and Pediatrics since 2005. Dr. Gilliam is also the founder and Director of the University of Chicago’s Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive Health, which conducts research to improve the health, education and wellbeing of adolescents. Prior to joining the University of Chicago, Dr. Gilliam was an Assistant Professor of Obstetrics and Gynecology at the University of Illinois at Chicago, where she also served as Adjunct Faculty to the Division of Epidemiology and Biostatistics in the School of Public Health. Dr. Gilliam received a B.A. in English from Yale University, an M.A. in Philosophy and Politics from the University of Oxford, an M.D. from Harvard Medical School and an M.P.H. in Epidemiology and Biostatistics from the University of Illinois at Chicago. She is a member of the National Academy of Medicine.

View Linkedin Profile

Jeri Hilleman

Jeryl “Jeri” Hilleman has served as a member of our board of directors since March 2021. Ms. Hilleman currently serves as Chairman of the board of Omada Health and is a Director of SI-Bone since December 2019, Novocure since July 2018, and Minerva Neurosciences since July 2018. Prior to her decision to focus on board responsibilities full time in 2020, Ms. Hilleman served as a life sciences executive and Chief Financial Officer for more than 20 years at multiple public companies, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel. Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School of the University of Pennsylvania. She is a member of the 1999 class of Henry Crown Fellow and the Aspen Global Leadership Network at the Aspen Institute.

View Linkedin Profile

Rustem Ismagilov, Ph.D., Co-founder

Rustem F. Ismagilov, Ph.D. is one of our co-founders and has served on our board of directors since June 2013. Dr. Ismagilov is a Professor of Chemistry and Chemical Engineering and the Director of the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology, where he has been employed since July 2011. From July 2001 to June 2011, Dr. Ismagilov held various positions of increasing responsibility at the University of Chicago, including as a Professor in the Department of Chemistry. Dr. Ismagilov received a B.S. from the Russian Academy of Sciences and a Ph.D. from the University of Wisconsin, Madison and completed postdoctoral training at Harvard.

View Linkedin Profile

Matt Posard

Matthew L. Posard has served on our board of directors since March 2016. Mr. Posard is a Founding Principal at Explore-DNA, Inc., a life sciences and diagnostics consulting firm, a position he has held since March 2016. Mr. Posard served as President and Chief Commercial Officer of GenePeeks, Inc. from February 2017 to April 2018 and as Executive Vice President and Chief Commercial Officer of Cardiff from March 2015 to May 2016. Mr. Posard also held various executive roles at Illumina from February 2006 to February 2015, including most recently as Senior Vice President, General Manager of New and Emerging Markets. Mr. Posard serves as Chairman of Nautilus Biotechnology, Inc. since January 2019, Stemson Therapeutics, LLC since March 2019, and DermTech, Inc. since July 2016. Mr. Posard also serves on the board of directors of Halozyme Therapeutics, Inc. since March 2013. Mr. Posard received a B.A. in Management Science from the University of California, San Diego.

View Linkedin Profile

Randy Scott, Ph.D.

Randal Scott, Ph.D. has served on our board of directors since February 2016. Dr. Scott is a co-founder and Chairman of the board of directors of Genome Medical, Inc., a genomic medicine company founded in August 2016. Previously, Dr. Scott was a co-founder of Invitae Corporation where he served as Chairman of the board of directors and Chief Executive Officer from August 2012 to January 2017 and Executive Chairman from January 2017 to August 2019. Prior to Invitae, Dr. Scott co-founded Genomic Health, where he served as Chairman of the board of directors and Chief Executive Officer from August 2000 to 2009 and Executive Chairman from 2009 to August 2012. Dr. Scott has also served on the board of directors of BridgeBio Pharma, Inc. since June 2020 and Freenome Holdings, Inc. since December 2017. Dr. Scott received a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.

View Linkedin Profile

Scientific Advisory Board

Rustem Ismagilov, Ph.D., Chair

Walter Koch, Ph.D.

Jane Schwebke, M.D.

Recent News

Excellence is what we stand for. Literally. It’s not just that Talis is actually the Latin word for “excellent”, it is also our mission to deliver excellence in the field of point-of-care diagnostics. We strive to improve healthcare for all through purpose-driven, accessible diagnostic solutions—so healthcare professionals can make improved treatment decisions for infectious diseases and provide peace of mind for patients.

See all press releases

Join Our Team

See Opportunities

Talis System

Learn More

Follow Us

Linkedin